PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201700020C — THE PURPOSE OF THIS MODIFICATION IS TO: (1) EXTEND THE PERIOD OF PERFORMANCE

THE PURPOSE OF THIS MODIFICATION IS TO: (1) EXTEND THE PERIOD OF PERFORMANCE is a federal NONE award for Department of Health and Human Services (HHS) held by REGENERON PHARMACEUTICALS, INC.. Estimated value $611.3M ($-5,232,672 obligated). Current period of performance ends Sep 24, 2027. Last award drew 1 bidder.

$611.3M
Estimated Value
$-5,232,672
Obligated
Sep 24, 2027
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

REGENERON PHARMACEUTICALS, INC. holds $-7,005,694 across 6 federal awards. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 24, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract numberHHSO100201700020C
AgencyDepartment of Health and Human Services (HHS)
IncumbentREGENERON PHARMACEUTICALS, INC.
UEIN3F9MH7E6HD6
NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN13
PoP end (current)Sep 24, 2027
Obligated$-5,232,672

THE PURPOSE OF THIS MODIFICATION IS TO: (1) EXTEND THE PERIOD OF PERFORMANCE

Recompete timing

Public
Expiring in 404 days

Current PoP ends Sep 24, 2027 (404 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Watch this contract — one email →

Incumbent footprint

Public record

REGENERON PHARMACEUTICALS, INC.$-7,005,694 obligated across 6 awards (firm-wide, all agencies).

Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for HHSO100201700020C
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open REGENERON PHARMACEUTICALS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract HHSO100201700020C?

HHSO100201700020C (THE PURPOSE OF THIS MODIFICATION IS TO: (1) EXTEND THE PERIOD OF PERFORMANCE) is a Department of Health and Human Services (HHS) award with an estimated value of $611.3M, currently held by REGENERON PHARMACEUTICALS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on HHSO100201700020C?

REGENERON PHARMACEUTICALS, INC. is the incumbent with $-7,005,694 across 6 related awards in SCOUT’s public footprint. The current period of performance ends Sep 24, 2027.

When does HHSO100201700020C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 24, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSO100201700020C